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Background: Allogeneic stem cell transplantation (alloSCT) is the preferred option of postremission therapy for
high-risk patients suffering from acute myeloid leukemia (AML). Therefore, monitoring life satisfaction (LS) of
long-term survivors following alloSCT is becoming increasingly important for oncologists. The aim of the study was
to evaluate individual survivor priority of various general and health-related domains of life and their satisfaction
with these domains. Furthermore, we investigated the impact of general and health-related LS on resilience, anxiety,
depression and quality of life in AML survivors following alloSCT.
Methods: Forty-one AML survivors (median age at time of assessment = 49.0 years) who had undergone alloSCT
(median time since transplantation = 3.1 years) were enrolled in the study. Psychosocial parameters were assessed
using the following instruments: FLZM (Questions on Life Satisfaction), EORTC QLQ-C30, HADS (Hospital Anxiety and
Depression Scale) and the RS-25 (Resilience Scale-25 items). Correlation analyses were computed to reveal the
associations between the different questionnaires.
Results: Independence from help or care, well-regulated living conditions and financial security contributed
positively to LS, whereas being off work due to health-reasons and dissatisfaction with physical aspects were
negatively associated to the subjective feelings of overall satisfaction. Moreover, a high quality of life was strongly
positively correlated with LS (Spearman’s rho general LS: 0.643 and health-related LS: 0.726, both p < 0.001). A high
degree of resilience was also strongly positively correlated with better LS (general LS: 0.700, health-related LS: 0.675,
both p < 0.001). Symptoms of anxiety and depression were associated with an impaired general LS (anxiety: −0.674,
depression: −0.698, both p < 0.001).
Conclusions: Our results indicate that LS should be considered an important key contributor to the survivors’
well-being following alloSCT. Thus, identifying protective psychological and physical factors that relieve stressors is
of high importance in order to support long-term AML survivors with their special needs.
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Due to continuous optimization of chemotherapy and
supportive care, the prognosis for patients suffering from
acute myeloid leukemia (AML) has steadily improved
over the last decades. As a consequence of these im-
provements, the quality of life of patients has become an
important parameter to assess [1]. Aggressive treatment* Correspondence: Susanne.Amler@ukmuenster.de
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unless otherwise stated.protocols can cause somatic late effects as well as psy-
chosocial disorders [2-7]. Thus, a major challenge re-
mains in the facilitation of an effective treatment that is
also associated with a reliable, high quality of life.
To date, only a few studies have analyzed quality of life
in AML survivors following alloSCT [8-10]. Messerer
et al. demonstrated that due to a lack of studies concern-
ing long-term follow-up, the relevance of the survivors’
quality of life often remains unclear. The authors postu-
lated a significantly worse long-term impact of alloSCT on
quality of life compared to conventional chemotherapyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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autologous or allogeneic haematopoietic stem cell trans-
plantation from 33 publications which included about
2800 patients. Their results showed that quality of life
decreased directly following transplantation, increased as
date of discharge approached and continued to improve
thereafter. Quality of life levels measured a year later were
comparable to those measured a few weeks prior to trans-
plantation [12].
The EORTC QLQ-C30 is the most widely used ques-
tionnaire in Europe that assesses quality of life in cancer
patients [13]. Unfortunately, the advancement of re-
search regarding the quality of life of adult AML survi-
vors following alloSCT is slow [14]. It is possible that
the EORTC QLQ-C30 core questionnaire provides only
limited insight into the quality of life in cancer survivors.
Kopp et al. reported that the EORTC QLQ-C30 affords
insight that concerns mainly the physical aspects of
quality of life and helps to identify symptoms, which de-
crease quality of life from the patients’ perspective [15].
However, some additional aspects of the quality of life
concept still need to be addressed. Survivors’ self-
assessed priority of and their satisfaction with various
life domains often remain unclear [16]. The Questions
on Life SatisfactionModules (FLZM) is a validated ques-
tionnaire for assessing general and health-related quality
of life [17]. The specific feature of this multidimensional
construct is that it distinguishes between a person’s indi-
vidual priority of multiple life domains and his/her own
subjective satisfaction within each domain. The respon-
dent evaluates each item twice, once for the subjective
importance of the various aspects of general life and
health conditions, and once for the degree of satisfaction
in this domain. These two ratings are combined into a
weighted satisfaction score. Presently, the multidimen-
sional FLZM is a well-established tool used to measure
LS in different oncological settings. [18-21]. To our
knowledge, no study has yet been published on specific
analysis of self-reported LS by using the FLZM in AML-
survivors after alloSCT. We have therefore implemented
the FLZM questionnaire, which provides a better under-
standing of survivors’ special needs.
Furthermore, psychological resilience, general living
conditions and current life situations are rarely investi-
gated. However, resilience could play an important role
in addressing issues relating to the survivors´ satisfaction
with life. Results of a study by Schumacher et al. re-
vealed a strong correlation of resilience with quality of
life [22].
Psychosocial care should no longer only focus on a
limited number of psychological needs. In order to gain
a better understanding of patients´ needs, it is important
to identify a broader spectrum of psychological and so-
cial factors influencing patients´ well-being. Filtering keyareas of need should be the first step to develop effective
support care [23]. Using additional assessment tools, and
thus gaining more extensive information concerning
special issues, may help to develop a more accurate and
systematic response to the urgent needs of individual
patients.
Therefore, our cross-sectional study aimed at assessing
LS by implementing the less commonly used FLZM
questionnaire in long-term survivors who had received
alloSCT and had been in complete remission for at least
six months prior to evaluation. Since FLZM comparative
data are available, we also compared our AML specific
study sample with normative data from a representative
German sample and with data from other cancer pa-
tients. In this way we expected to obtain a better insight
into survivors’ importance rates and the satisfaction of
their needs. Secondly, we investigated the association
between LS within the FLZM and additional psycho-
logical factors such as resilience, anxiety, depression and
quality of life by using other well-established question-
naires within the same study sample. In doing so we
analyzed the ability of the FLZM to integrate with the
other instrument tools, therefore enabling the use of the
FLZM as an insightful and informative additional ques-
tionnaire. In addition, information on social issues,
demographic and work-related variables was included.
The findings of our study will help to identify important
information regarding the special needs associated with
AML cancer survivors after alloSCT.
Methods
Instruments
The following instruments were used: Questionnaire on
Life Satisfaction FLZM [17] (in the original German:
FLZ-M, Fragen zur Lebenszufriedenheit Module), Quality
of Life Questionnaire EORTC QLQ-C30 [24,25], Resi-
lience Scale RS-25 [26,27] and Hospital Anxiety and De-
pression Scale HADS [28,29]. The questionnaires are
well-established evaluation tools used in psychological
research.
In Questions on Life Satisfaction FLZM, subjects assess
their subjective general and health-related LS based on
the subjective importance of certain aspects of multiple
life domains and the satisfaction within these domains.
Both modules consist of eight dimensions. The general
module addresses the following: ‘friends/acquaintances’,
‘leisure time/hobbies’, ‘health’, ‘income/financial security’,
‘occupation/work’, ‘housing/living conditions’, ‘family life/
children’ and ‘partner relationship/sexuality’. The health-
related module addresses these issues: ‘physical condition/
fitness’, ‘ability to relax/stay on an even keel’, ‘energy/zest
for life’, ‘mobility (e.g., walking, driving)’, ‘vision and
hearing’, ‘freedom from anxiety’, ‘freedom from aches
and pains’ and ‘independence from help/care’. For each
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First, the subjects rate their subjective importance of each
dimension on a scale of 1 (‘not important’) to 5
(‘extremely important’). Secondly, they assess their satis-
faction with each dimension on a scale of 1 (‘dissatisfied’)
to 5 (‘very satisfied’). The ratings for importance and satis-
faction in each dimension are combined into a weighted
satisfaction score by calculating the formula: weighted
satisfaction = (importance rating – 1) × (2 × satisfaction
rating – 5). Possible dimension-specific weighted scores
range from −12 to 20. Means and standard deviations
were calculated for the weighted scores of each dimension.
The two FLZM total scores, i.e. the general LS and health-
related LS scores, are calculated by summing up the eight
general and eight health-related scores. The total scores
range from −96 to 160. Negative scores indicate dissatis-
faction; positive scores indicate satisfaction of the specific
dimension. The higher the score, the higher the subjective
importance and individuals’ LS. Zero indicates no subject-
ive importance [17]. The internal consistency as measure
of the reliability for the FLZM General and FLZM Health
total scores was shown to be high (Cronbach’s alpha =
0.82 and 0.89, respectively) [17,30]. In our study sample,
internal consistency was also good with a Cronbach’s
alpha of 0.83 for the general and 0.90 for the health-
related module.
The EORTC Quality of Life Questionnaire (EORTC
QLQ-C30 Version 3.0) consists of five functional scales
(‘physical’, ‘role’, ‘emotional’, ‘cognitive’ and ‘social’).
Three symptom scales, and six single items assess spe-
cific side effects. The ‘global quality of life scale’, consists
of two items ‘How would you rate your overall health
during the past week?’ and ‘How would you rate your
overall quality of life during the past week?’ [24]. Raw
scores are linearly transformed into scores ranging from
0 to 100, with a high score representing a higher re-
sponse level. Thus, a high score in the functioning scales
and the global quality of life scale indicates a high level
of functioning, whereas a high score for a symptom scale
or item reflects a high level of symptomatology [25]. The
QLQ-C30 has been tested in EORTC filed studies [24]
and is nowadays a very well validated instrument. In
our study the reliabilities were acceptable or excel-
lent: Cronbach’s alpha = 0.77 (physical), 0.86 (role), 0.90
(emotional), 0.86 (cognitive), 0.85 (social), fatigue (0.84),
0.93 (pain) and 0.89 (global scale). The reliability of fa-
tigue was not comparable, because of missing values in
our study sample.
The Resilience Scale (RS-25) (German Version) was
originally developed by Gail M. Wagnild and Heather
M. Young [27]. Items are scored on a seven-point Likert
scale, ranging from 1 (‘strongly disagree’) to 7 (‘strongly
agree’). The total score is calculated by summing up the
25 items of the resilience scale. Possible sum scoresrange from 25 to 175, with higher scores reflecting higher
resilience [27]. Internal consistency of the German version
of the RS-25 Scale [26] was evaluated in a large com-
munity sample of the German population (n = 2031, aged
4–95 years) with a high Cronbach’s alpha of 0.95. In the
current study, Cronbach’s alpha was 0.91 for the whole
scale.
The Hospital Anxiety and Depression Scale (HADS)
(German Version) [29] was originally developed by
Zigmond and Snaith [28]. Each of the 14 question items,
seven for each subscale, is a four point (0–3) category.
The overall possible sum scores range from 0 to 21 for
anxiety as well as for depression. Lower scores (0–7) in-
dicate clinical stability; whereas higher positive scores
(greater or equal to 11) suggest potential need for psy-
chiatric treatment.
The well-validated German version of the HADS
showed acceptable internal consistencies for both scales
[29,31]. In our study, internal consistency was good
(Cronbach’s alpha of 0.86 for both the depression and
anxiety scale) and excellent for the whole scale of the
HADS: Cronbach’s alpha = 0.92.
Clinical data from survivors such as type of AML, age
at diagnosis and randomized induction regime were pro-
vided by the central database of the study office. In
addition, general data about survivors’ current life situa-
tion were collected, including socio-demographic cha-
racteristics such as age, sex, education, income, marital
status and actual size of household, respectively.
Setting and population
This quality of life study is based on a subgroup of AML
survivors who had previously undergone treatment ac-
cording to protocol of the multicenter clinical AML Co-
operative Group (AMLCG 99) trial for newly diagnosed
primary AML [32]. Inclusion criteria for the quality of
life study were: 1. AML patients were 16–60 years of age
at time of initial diagnosis and had already received
conditioning therapy. 2. Patients achieved first complete
remission following conditioning treatment and 3. Sub-
sequent alloSCT was performed at least 6 months prior
to assessment. Taking these criteria into account, 84 eli-
gible patients were deemed suitable for quality of life
assessment. These patients were treated at 27 various
German cancer centers. They received transplantation
between December 1999 and August 2005. We know-
ingly accepted the relatively long period between time of
transplant and assessment due to the pilot character of
the study. The AMLCG 99 trial was approved by the Ethics
Committee of the University of Muenster (Muenster,
Germany) and was conducted in accordance with the eth-
ical standards established in the 1964 Declaration of
Helsinki and its later amendments. Survivors meeting in-
clusion criteria for the quality of life study were informed
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informed consent was given by all survivors prior to trial
inclusion. The quality of life assessment was conducted in
an outpatient setting.
Data collection
Data were collected from June 2006 to March 2007. One
patient was untraceable due to unknown address. Three
patients were not contacted due either to serious psy-
chological difficulties, premature withdrawal, or relapse.
Therefore, the questionnaires including a separate infor-
mation letter regarding the quality of life study were sent
to the remaining 80 patients with a pre-addressed, pre-
paid, return postage label. Survivors expressed their con-
sent by voluntarily completing the questionnaires and
returning them via post to the study office. 41 survivors
complied, representing a response rate of 51%.
Data analyses
Data collection, transformation and the statistical ana-
lyses of the data were performed using IBM SPSS Statis-
tics 20.0 for Windows (IBM Corporation, Somers, NY,
USA) and SAS software, Version 9.2 (SAS Institute Inc.,
Cary, NC, USA).
To examine a potential effect between LS and assess-
ment on global quality of life, resilience, anxiety and de-
pression, rank correlations were calculated using the
method of Spearman [33]. Correlation coefficients were
interpreted using the scale provided by Salkin, where an r
between 0.8 and 1.0 is defined as ‘very strong’, between 0.6
and 0.8 as ‘strong’, between 0.4 and 0.6 as ‘moderate’, bet-
ween 0.2 and 0.4 as ‘weak’ and between 0.0 and 0.2 as ‘very
weak’ or ‘no relationship’ [34]. In order to guarantee com-
parability with normative data and other samples, group
comparisons regarding the FLZM total scores are pre-
sented as mean with standard deviation, otherwise me-
dians with interquartile ranges (IQR) are presented.
Nevertheless, in order to do justice to that effort with
the relatively small study sample size, FLZM total scores
(e.g. general LS, health-related LS) were compared be-
tween categorical groups using non-parametric Mann–
Whitney U test [35,36] for two group comparisons,
whereas the Kruskal-Wallis test was performed on three
or more groups [37]. Differences between proportions
were analyzed using Fisher’s exact test [38]. Inferential
statistics are intended to be exploratory (hypotheses
generating), not confirmatory, and are interpreted ac-
cordingly. P-values are considered statistically significant
in case p < 0.05.
Results
Study sample
We identified a total of 41 AML survivors, aged 23–
66 years at time of assessment, who fulfilled thequestionnaires. Among those, 44% were men (n = 18) and
56% of the participants were women (n = 23). With regard
to age at time of assessment, there were no significant age
differences between men and women (median: 47.0 vs.
49.0, p = 0.636; data not shown). At the time of diagnosis,
66% of the participants had de novo AML (n = 27), 29%
suffered from secondary AML (n = 12) and 5% had high-
risk myelodysplastic syndrome (n = 2). Participating sur-
vivors were followed up with a median of 3.1 years post
alloSCT (ranged from 8 months to 7 years).
Table 1 summarizes the characteristics in a compari-
son between participants and survivors who declined
participation in the quality of life study. There were no
significant differences between participants and non-
participants regarding sex, age at diagnosis, type of
conditioning treatment, donor or occurrence of graft-
versus-host disease. Differences were found between the
two groups regarding type of hematological disease: a
higher proportion of participants than non-participants
had secondary AML and high-risk myelodysplastic syn-
drome (p = 0.022). Its participating survivors were slightly
older than the survivors who declined participation
(median: 49.0 vs. 44.0; p = 0.046).
Survivors’ general and health-related LS
Figure 1 shows the weighted LS mean scores of the study
population for the eight different dimensions, separated
by the general and health-related modules. Analysis of the
general life domains showed that the study participants
were most satisfied with their ‘housing/living conditions’
(mean = 9.5), closely followed by ‘family life/children’
(mean = 9.2) and ‘health’ (mean = 8.3). By contrast, the
minimum weighted LS value were found for ‘occupation/
work’ (mean = 2.5), followed by ‘income/financial security’
(mean = 3.3). When investigating the different dimensions
of the health-related module, participants were most satis-
fied with their ‘independence from help/care’ (mean = 14.7),
followed at some distance by ‘mobility’ (mean = 9.9) and
‘vision and hearing’ (mean = 8.9). Here, the participants
were less satisfied with their ‘physical condition/fitness’
(mean = 4.0), followed by ‘ability to relax/stay on an even
keel’ (mean = 5.7).
Correlations between the FLZM and other questionnaires
Correlations between weighted general and health-
related LS and the other parameters were computed.
The global quality of life scale (2-item) of the QLQ-C30
showed a strong correlation with survivors’ weighted LS
(Spearman’s rho r = 0.643 for general LS and r = 0.726 for
health-related LS; both p < 0.001). Furthermore, there was
a strong positive correlation between ‘emotional func-
tioning’ and the general LS (r = 0.687) and a moderate
correlation with the health-related LS (r = 0.564), both
p < 0.001. ‘Physical-’, ‘cognitive-’ and ‘role functioning’
Table 1 Characteristics of the AML survivors (n = 80)
Survivors contacted for
the quality of life study
Participating
survivors (P)
Survivors who declined
participation (NP)
p-value
P vs. NP
No of survivors 80 41 39
Sex, N (%) 0.509
Male 38 (47) 18 (44) 20 (51)
Female 42 (53) 23 (56) 19 (49)
Age at diagnosis (years) 42.0 43.0 40.0 0.070
Median (IQRb) (34.0 − 49.0) (37.0 − 51.0) (32.0 − 47.0)
Age at time of assessment (years) 45.5 49.0 44.0 0.046
Median (IQR) (38.0 − 52.5) (41.0 − 54.0) (38.0 − 49.0)
Type of AML, N (%) 0.022
De Novo AML 62 (77) 27 (66) 35 (90)
Secondary AMLa 15 (19) 12 (29) 3 (8)
High-risk myelodysplastic syndrome 3 (4) 2 (5) 1 (3)
Induction therapy, N (%) 0.509
TAD-HAM 38 (47) 18 (44) 20 (51)
HAM-HAM 42 (53) 23 (56) 19 (49)
Time interval since alloSCT (years) 3.3 (2.4 − 4.8) 3.1 (2.4 − 4.2) 3.7 (2.5 − 5.3) 0.191
Median (IQR)
Donor, N (%) 0.062
Related 58 (72) 26 (63) 32 (82)
Unrelated 22 (28) 15 (37) 7 (18)
HLAc, N (%) 0.258
Matched 73 (91) 39 (95) 34 (87)
Mismatched 7 (9) 2 (5) 5 (13)
GvHDd after transplantation, N (%) 1.000
Yes 52 (68) 26 (67) 26 (68)
No 25 (32) 13 (33) 12 (32)
aSecondary AML included AML after myelodysplastic syndrome or therapy-related AML.
bIQR = Interquartile range.
cHLA = human leukocyte antigen. dGvHD = graft-versus-host-disease.
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total scores (general LS: r = 0.529, r = 0.539, r = 0.580; all
p < 0.001; health-related LS: r = 0.599, r = 0.545, r = 0.554;
all p < 0.001). ‘Social functioning’ also correlated moder-
ately with general LS (r = 0.515; p < 0.001) but correlated
weakly with health-related LS (r = 0.244; p > 0.05). HADS
anxiety and depression scores showed a strong negative
correlation with survivors’ general LS (anxiety: r = −0.674,
depression: r = −0.698; both p < 0.001). A similar negative
effect was seen for correlation with health-related LS
(anxiety: r = −0.536, depression: r = −0.739; both p < 0.001).
In contrast, a strong positive correlation was found for
LS with resilience (general LS: r = 0.700, health-related
LS: r = 0.675; both p < 0.001). Bivariate correlation coeffi-
cients for the general LS and health-related LS total scoreswithin the FLZM and the other instruments are summa-
rized in Table 2.
Sociodemographic and medical characteristics associated
with the survivors’ LS
The association between sociodemographic and clinical
characteristics was investigated for both general LS and
health-related LS (Table 3). The largest association was
observed for employment status. Survivors who had re-
tired for health reasons or were currently on sick leave
had significantly worse health-related LS (p = 0.033).
Moreover, in secondary AML the average scores for gen-
eral LS and health-related LS were noticeable lower
(33.8 and 44.9, respectively) than in de novo AML (57.8
and 69.5, respectively). Not surprisingly, younger people
General Life Satisfaction
Health-related Life Satisfaction
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
friends/ acquaintances 7.2
(5.9)
leisure time/ hobbies 4.4
(6.7)
health 8.3 (8.4)
income/ financial security
3.3 (7.2)
occupation/ work 2.5 (7.2)
housing/ living conditions
9.5 (5.5)
family life/ children 9.2
(8.9)
partner relationship/
sexuality 6.5 (8.6)
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
physical condition/
fitness 4.0 (7.3)
ability to relax/ stay on
an even keel 5.7 (5.3)
energy/ zest for life
7.0 (8.6)
mobility (e.g., walking,
driving) 9.9 (8.9)
vision and hearing 8.9
(8.6)
freedom from anxiety
6.8 (7.7)
freedom from aches
and pains 7.6 (9.1)
independence from
help/ care 14.7 (7.2)
Figure 1 Life satisfaction as measured by the FLZM. Group means with 1-fold standard deviations (displayed in brackets) are reported (n = 41).
The distances from the center point indicate the weighted scores of each item. The marked area enclosed between the eight items represents
the total general or health-related life satisfaction within the study group.
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pected, decline with growing age. No significant effects on
LS were found for the other sociodemographic factors.Discussion
As scientific and medical progress in alloSCT are likely
to increase the number of long-term survivors, these
Table 2 Correlations (Spearman’s rho): life satisfaction (FLZM), functioning scales of EORTC QLQ-C30, resilience scale RS-25 and HADS
General LS Health-related LS Global quality Physical
functioning
Emotional
functioning
Cognitive
functioning
Role
functioning
Social
functioning
Resilience
scale
HADS-D-anxiety
Health-related life satisfaction 0.711**
Global quality of life (QOL) 0.643** 0.726**
Physical functioning 0.529** 0.599** 0.781**
Emotional functioning 0.687** 0.564** 0.647** 0.591**
Cognitive functioning 0.539** 0.545** 0.511** 0.374* 0.509**
Role functioning 0.580** 0.554** 0.681** 0.601** 0.626** 0.598**
Social functioning 0.515** 0.244 0.403** 0.436** 0.635** 0.377* 0.408**
Resilience Scale 0.700** 0.675** 0.538** 0.495** 0.713** 0.513** 0.488** 0.409**
HADS-D-Anxiety −0.674** −0.536** −0.525** −0.526** −0.828** −0.487** −0.438** −0.559** −0.722**
HADS-D-Depression −0.698** −0.739** −0.751** −0.609** −0.699** −0.577** −0.594** −0.493** −0.695** 0.720**
*p < 0.01. **p < 0.001.
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Table 3 FLZM-general LS and FLZM-health LS total scores for the AML survivors study sample by sociodemograhic and
clinical factors
n* FLZM general LS p-value FLZM health p-value
Total 40 50.7 (39.1) 64.9 (48.0)
Age at diagnosis (years) 40 0.645 [−0.612;1.902]a 0.305b −0.412 [−1.959; 1.136]a 0.593b
Age at time of evaluation (years) 40 0.601 [−0.635;1.838]a 0.331b −0.610 [−2.127; 0.907]a 0.420b
Time interval since alloSCT (years) 40 −0.081 [−8.409;8.247]a 0.984b −6.338 [−16.197;3.521]a 0.201b
Sex 0.542 0.702
Male 18 46.3 (50.6) 59.4 (54.3)
Female 22 54.1 (28.2) 67.5 (43.1)
Type of AML 0.272 0.096
De Novo AML 27 57.8 (38.4) 9.5 (51.5)
Secondary AML 11 33.8 (41.1) 44.9 (37.8)
High-risk myelodysplastic syndrome 2 39.0 (15.6) 92.0 (0)
Marital status 0.466 0.717
Not married 9 37.1 (47.4) 66.6 (47.5)
Married 24 52.0 (39.9) 56.8 (54.3)
Separated/Divorced/Widowed 7 63.0 (28.4) 80.3 (22.7)
Employment status 0.238 0.033
Full-time 9 65.6 (30.7) 86.8 (24.2)
Part-time/Marginal 6 57.2 (47.5) 86.5 (38.2)
Currently off work due to illness 4 57.5 (30.7) 37.5 (68.3)
Retired for health reasons 11 24.8 (44.9) 25.8 (48.6)
Unemployed/Other 8 58.6 (35.2) 76.9 (35.1)
Educational level 0.099 0.070
Low (elementary school) 21 41.9 (43.1) 50.7 (46.4)
Middle (secondary school) 10 74.5 (27.2) 82.9 (52.4)
High (grammar school) 4 30.5 (34.5) 52.5 (58.9)
University 4 57.0 (35.3) 91.0 (8.8)
*Sample size varies due to missing or incomplete data.
aRegression coefficient beta with 95% confidence interval.
bp-value determines whether or not the null hypothesis that a particular predictor's regression coefficient is zero can be rejected.
Note: unless otherwise specified, means with 1-fold standard deviation are reported.
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social problems related to transplantation. In order to
offer each individual patient the maximum physical and
psychological advantage following this intensive therapy,
it is important to examine and identify protective psy-
chosocial factors [22]. The survivor’s individual priority
of various life domains and their satisfaction with these
domains often remain unclear. This necessitates the
need to know in detail how satisfied a person is with a
specific aspect of life, as well as how important this as-
pect is to that person. Therefore, the main focus of our
study was the assessment of LS in long-term AML survi-
vors who underwent alloSCT.
In our study, we detected different levels of survivors’
importance and satisfaction for a variety of life domains.
In terms of the general LS, we found the largest valuesin ‘housing/living conditions’ and ‘family life children’.
This not only means that housing situation and family
structure are of great importance for the majority of the
AML survivors, but that they also report a very high sat-
isfaction in these two specific life domains. The lowest
values were found for the domains ‘income/financial se-
curity’ and ‘occupation/work’. This ranking seems to
confirm that being employed and ensuring a good steady
income are one of the most important aspects of life, yet
a high proportion of the study group are dissatisfied with
their employment conditions. Differences in health-
related LS were also reflected when comparing the occu-
pational status among SCT survivors: unemployment
due to illness or retirement for health reasons had a sig-
nificantly negative impact on health-related LS. Our
finding is in line with a study from Sweden concerning
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a median follow up of 8 years post alloSCT [39]. The au-
thors stated that being employed is an important goal
after alloSCT. In general, employment is associated with
better well-being among survivors previously treated
with hematopoietic SCT [40]. Other studies also show
that the most prevalent problems among SCT survivors
included concerns about keeping their job, worries
that they will need to take a disability pension or a paid
leave of absence [41]. This financial and employment
stress leads many survivors to a poorer quality of life
[40,42-44]. It should be noted that more than half of the
participants (56%) of our study sample were unemployed
at time of follow up which may explain the great impact
on the survivors’ dissatisfaction with their financial sta-
tus. Moreover, domains of the health-related LS showed
a high degree of satisfaction among ‘independence from
help/care’ and ‘mobility’, whereas survivors’ LS was most
negatively affected by ‘physical condition/fitness’. How-
ever, physical fitness limitations are a commonly known
side effect, especially among survivors following SCT
[45-47]. Other studies noted that a substantial percen-
tage of AML patients had difficulties with physical acti-
vities. In Zittoun et al. 49% out of a total of 35 alloSCT
patients in complete remission still reported difficulties
in taking a long walk or doing work or household jobs
[7]. Furthermore, it is not surprising that survivors are
not completely satisfied in the domains that reflect psy-
chological components, such as ‘ability to relax/stay on
an even keel’ , ‘freedom from anxiety’, ‘energy/zest for life’
and ‘freedom from aches and pains’. This may reflect the
survivors’ greater risk for symptoms of anxiety and de-
pression following an aggressive cancer therapy. Con-
sistent with previous studies assessing the impact of
psychological distress on quality of life for hematological
cancer survivors, higher levels of psychological morbidity
(e.g. anxiety and depression) were associated with survi-
vors reporting lower satisfaction with health [40,48,49].
In direct comparison to a study with a representative
sample of the German population by Henrich and
Herschbach [17], in our study sample the FLZM general
LS total scores were on average about 10 scores lower
than the representative sample (mean with standard de-
viation, sample size): 60.5 (37.3, n = 2534) vs. 50.7 (39.1).
For the FLZM Health LS the total scores were equally
lower in the study sample than in the representative
sample: 74.4 (41.5) vs. 64.9 (48.0). As of yet, there are no
directly comparable values for the FLZM in survivors
suffering from AML following alloSCT. With regard to
the specific eight life domains, in both the representative
and the study sample, the highest impacts were observed
for ‘housing/living condition’ and ‘family life/children’
and the lowest values in the domain ‘occupation/work’
[17]. A similar effect can also be observed for the eightFLZM Health modules with highest value for ‘indepen-
dence from help/care’ and lowest values for ‘physical con-
dition/fitness’ and ‘ability to relax’ in both samples [17].
When comparing our results with the data from other
cancer patients, patients under treatment scored on
average slightly lower in the FLZM General LS [17]. In
contrast, those cancer patients in rehabilitation or in re-
mission assessed their life satisfaction as higher than the
participants in our study.
Overall, our study sample of AML survivors following
alloSCT are not as satisfied with their subjective life
satisfaction as the representative sample, but are more
satisfied than acute cancer patients currently under
treatment.
The correlation of the FLZM with the other instru-
ments demonstrates a strong or moderate positive effect
of quality of life, including all functional scales of the
EORTC QLQ-C30 and of the psychological well-being
on survivors’ LS. In contrast, the subscales anxiety and
depression of the HADS, revealed a strong negative im-
pact on survivors’ LS. These results are in accordance
with other studies, in which a positive correlation was
found between resilience and LS, and a negative correl-
ation with psychological stressors [16,50,51].
However, with respect to survivors who were con-
tacted, yet decided not to respond, the reasons for not
participating in the quality of life study are unclear. It is
possible that some of the long-term survivors no longer
wanted to be confronted with their former disease. Some
of them might have moved on with their lives. In fact,
we had detailed information from one non-responder
that he no longer wanted to think intensively about his
former disease. Response rates might also be dependent
on the centers’ specific size and specialization. Interes-
tingly, the survivors responding to the questionnaires
were older at time of assessment and had a higher risk
profile (e.g. higher age, higher rate of transplantations
from unrelated donors, less de novo AML and more sec-
ondary AML and high-risk myelodysplastic syndrome).
Thus, it is possible that these survivors, having a gene-
rally lower quality of life, may be more motivated to
answer questionnaires. Compared to older survivors,
younger survivors may have been less likely to respond,
due to different priorities in terms of families and job
duties, which is in line with a study by Hall et al., sug-
gested that younger survivors may be more likely to have
competing time demands [43].
Despite these possible explanations, all survivors were
in complete remission at the time of questionnaire
evaluation, and there were no significant differences in
treatment-related characteristics between participants
and non-participants. It should be noted, however, that
our findings are restricted due to the cross-sectional de-
sign of our study. Furthermore, although the sample size
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by the fact that being a rare disease, the recruitment of
former AML patients is a limiting factor. The overall re-
sponse rate was more than 50%.
Conclusion and future implications
In order to adequately support long-term survivors with
special needs, physicians and psychologists need to look
carefully at survivors’ satisfaction with life and the sub-
jective importance of specific life domains.Whereas the
assessment of quality of life is increasingly common in
studies, it often remains unclear how important and sat-
isfied a specific life domain is for an individual patient.
Our study indicates that the FLZM questionnaire corre-
sponds well with other validated instruments. Our find-
ings emphasize that the use of the FLZM provides
important information, which offers a broader spectrum
and more precise details of survivors’ quality of life. This
allows us to reach a clearer understanding of how best
to identify the needs of AML survivors and will help to
address such needs. Our pilot study has shown that LS
in AML survivors following alloSCT is an important
issue and its assessment provides valuable information
and insights that affect future research. Since our study
showed a substantial lack of satisfaction in terms of em-
ployment issues, physicians and psychologists should
also focus their efforts on areas such as financial support
services. A good example would be providing assistance
for reintegration into social and professional life. More-
over, it is very important to offer interventions at the
earliest possible stage of clinical care that could prevent
psychological distress, and physical limitations could be
addressed in the form of special fitness programs follo-
wing alloSCT.
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